JPH085634A - Aqueous solution containing antigen - Google Patents
Aqueous solution containing antigenInfo
- Publication number
- JPH085634A JPH085634A JP16476094A JP16476094A JPH085634A JP H085634 A JPH085634 A JP H085634A JP 16476094 A JP16476094 A JP 16476094A JP 16476094 A JP16476094 A JP 16476094A JP H085634 A JPH085634 A JP H085634A
- Authority
- JP
- Japan
- Prior art keywords
- casein
- antigen
- aqueous solution
- whey protein
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、臨床検査の分野におい
て酵素免疫測定法、放射線免疫測定法、或は免疫比濁法
等の免疫測定を行う時に用いる抗原を含有した標準溶液
中の抗原の失活を防止し、安定して保存することができ
る水溶液に関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to the use of an antigen in a standard solution containing an antigen to be used in immunoassays such as enzyme immunoassay, radioimmunoassay or immunoturbidimetry in the field of clinical examination. The present invention relates to an aqueous solution which can prevent deactivation and can be stably stored.
【0002】[0002]
【従来の技術】免疫測定を行う時には、抗原を含有した
標準液が使用される。この標準液中の抗原は希薄である
ため、溶液中で著しく失活するものがある。特に、ホル
モン、酵素などの抗原の失活が激しい。従来、このよう
な失活の激しい抗原を安定して保存するために、凍結乾
燥などにより水分を除去し固体にして保存し、使用時に
水を加えてこの固体を溶解する方法がとられている。2. Description of the Related Art When performing an immunoassay, a standard solution containing an antigen is used. Since the antigen in this standard solution is diluted, some antigens are significantly inactivated in the solution. In particular, the inactivation of antigens such as hormones and enzymes is severe. Conventionally, in order to stably store such a highly inactivated antigen, a method has been used in which water is removed by freeze-drying or the like to be stored as a solid, and then water is added to dissolve the solid at the time of use. .
【0003】[0003]
【発明が解決しようとする課題】しかしながら、従来の
凍結乾燥による方法で作製される標準は、保存安定性は
良いが、使用時に水分を加えて固体状の抗原を溶解しな
ければならないため、操作が煩雑になり濃度誤差が生じ
易い。更に、溶解後には水溶液中の抗原が失活し濃度誤
差が生じ易くなる。このため、水分を加えて溶解すると
いう調製操作がない溶液状態の標準の検討が行わた結
果、抗原含有水溶液に牛血清アルブミンや血清などのタ
ンパク質を添加する改善が行われた。しかし、これらの
改善によっても保存安定性は1年間以上の長期間維持で
きないという問題点がある。However, although the standard prepared by the conventional freeze-drying method has good storage stability, it is necessary to add water at the time of use to dissolve the solid antigen. Is complicated and a density error is likely to occur. Furthermore, after dissolution, the antigen in the aqueous solution is inactivated, and a concentration error is likely to occur. Therefore, as a result of studying a standard in a solution state without a preparation operation of dissolving by adding water, improvement in adding proteins such as bovine serum albumin and serum to an antigen-containing aqueous solution was performed. However, even with these improvements, there is a problem that storage stability cannot be maintained for a long period of one year or more.
【0004】[0004]
【課題を解決するための手段】本発明者らは、上記問題
点を解決すべく鋭意検討した結果、カゼイン及び/又は
ホエイ蛋白を主成分とする水溶液中に抗原を含有させる
ことにより、水溶液中でも抗原の失活が小さく、1年以
上の長期間の保存安定性が維持できる抗原含有水溶液を
見いだし、本発明に到達した。Means for Solving the Problems The present inventors have conducted intensive studies to solve the above-mentioned problems, and as a result, by containing an antigen in an aqueous solution containing casein and / or whey protein as a main component, an aqueous solution containing The present inventors have found an aqueous solution containing an antigen which has a small inactivation of the antigen and can maintain the storage stability for a long period of one year or more, and reached the present invention.
【0005】即ち本発明は、抗原とカゼイン及び/又は
ホエイ蛋白からなることを特徴とする抗原含有水溶液で
ある。That is, the present invention is an antigen-containing aqueous solution comprising an antigen and casein and / or whey protein.
【0006】本発明においてカゼインとしては、牛乳中
のカゼインがあげられる。例えば、「第五版食品添加物
公定書解説書(廣川書店発行)」記載のカゼインを用い
ることができる。具体的には、α−カゼイン、β−カゼ
イン、γ−カゼイン、κ−カゼイン、λ−カゼインをあ
げることができる。カゼインの濃度は通常0〜2.00
w/v%、好ましくは0.05〜0.25w/v%であ
る。The casein in the present invention includes casein in milk. For example, casein described in the “Fifth Edition Food Additive Official Standard Manual (issued by Hirokawa Shoten)” can be used. Specific examples include α-casein, β-casein, γ-casein, κ-casein, and λ-casein. The concentration of casein is usually 0 to 2.00
w / v%, preferably 0.05 to 0.25 w / v%.
【0007】ホエイ蛋白としては、牛乳中のホエイ蛋白
があげられる。ホエイ蛋白としては、「食品衛生法 乳
及び乳製品の成分規格に関する省令」に記載されている
濃縮ホエイやホエイパウダーをあげることができる。ホ
エイ蛋白の濃度は通常0〜1.00w/v%、好ましく
は0.03〜0.15w/v%である。Examples of whey protein include whey protein in milk. Examples of whey proteins include concentrated whey and whey powder described in “Ministry Ordinance on Ingredients for Milk and Dairy Products in the Food Sanitation Law”. The concentration of whey protein is usually 0 to 1.00 w / v%, preferably 0.03 to 0.15 w / v%.
【0008】カゼインとホエイ蛋白を共存させることに
より、抗原を含有する水溶液の保存安定性を更に向上さ
せることができる。この時の濃度は、カゼイン0.03
〜2.00w/v%、ホエイ蛋白0.01〜1.00w
/v%が好ましく、特に好ましくは、カゼイン0.05
〜0.25w/v%、ホエイ蛋白0.03〜0.15w
/v%である。[0008] By coexisting casein and whey protein, the storage stability of the aqueous solution containing the antigen can be further improved. The concentration at this time was 0.03 casein.
~ 2.00 w / v%, whey protein 0.01 ~ 1.00 w
/ V%, particularly preferably 0.05% casein.
~ 0.25w / v%, whey protein 0.03 ~ 0.15w
/ V%.
【0009】抗原としては、ホルモン、酵素、抗体及び
ウイルスがあげられる。ホルモンとしてはインスリン、
甲状腺刺激ホルモン(TSH)、卵胞刺激ホルモン(F
SH)、ヒト絨毛性ゴナドトロピン(hCG)、黄体形
成ホルモン(LH)、プロラクチン等があげられる。酵
素としては神経特異エノラーゼ(NSE)等があげられ
る。抗体としてはIgE等があげられる。ウイルスとし
てはHBs等があげられる。これらのうち、好ましいも
のはホルモンであり、更に好ましいものはインスリンで
ある。[0009] Antigens include hormones, enzymes, antibodies and viruses. Insulin as insulin,
Thyroid stimulating hormone (TSH), follicle stimulating hormone (F
SH), human chorionic gonadotropin (hCG), luteinizing hormone (LH), prolactin and the like. Examples of the enzyme include nerve-specific enolase (NSE). Examples of the antibody include IgE. Examples of viruses include HBs. Of these, hormones are preferred, and insulin is more preferred.
【0010】[0010]
【実施例】以下、実施例により、本発明を更に説明する
が、本発明はこれに限定されるものではない。 実施例 インスリン標準溶液の保存安定性 a)カゼインとホエイ蛋白を主成分とするインスリン標
準溶液の作製 濃度が0.06w/v%カゼイン(牛乳製)、0.03
w/v%ホエイ蛋白(牛乳製)、0.1w/v%NaN
3、0.9w/v%NaCl含有0.02Mリン酸緩衝
水溶液にインスリンを添加し、10μg/ml、50μ
g/ml、125μg/ml、250μg/mlのイン
スリン標準液Aを作製した。 b)ウシ血清アルブミン(BSA)を主成分とするイン
スリン標準溶液の作製 濃度が1w/v%BSA、0.1w/v%NaN3、
0.9%NaCl含有0.02Mリン酸緩衝水溶液にイ
ンスリンを添加し、10μg/ml、50μg/ml、
125μg/ml、250μg/mlのインスリン標準
液Bを作製した。 c)保存安定性の検討 各濃度のインスリン標準液A及びBを4℃と25℃で保
存し、作製時、1カ月目、3カ月目、6カ月目、12カ
月目のインスリン濃度をグライザイムInsulin
(三洋化成工業(株)製)で測定し、インスリン濃度の
変化を調べた。結果を表1に示した。The present invention will be further described with reference to the following examples, but the present invention is not limited to these examples. Example Storage stability of insulin standard solution a) Preparation of insulin standard solution containing casein and whey protein as main components Concentration of 0.06 w / v% casein (made by milk), 0.03
w / v% whey protein (made of milk), 0.1 w / v% NaN
3. Insulin was added to a 0.02 M aqueous phosphate buffer solution containing 0.9 w / v% NaCl, and 10 μg / ml and 50 μm
g / ml, 125 μg / ml, and 250 μg / ml of insulin standard solution A were prepared. b) Preparation of insulin standard solution containing bovine serum albumin (BSA) as a main component. The concentration was 1 w / v% BSA, 0.1 w / v% NaN3,
Insulin was added to a 0.02 M phosphate buffer aqueous solution containing 0.9% NaCl, and 10 μg / ml, 50 μg / ml,
Insulin standard solutions B of 125 μg / ml and 250 μg / ml were prepared. c) Examination of storage stability Insulin standard solutions A and B at each concentration were stored at 4 ° C. and 25 ° C., and at the time of preparation, the insulin concentrations at 1 month, 3 months, 6 months, and 12 months were determined by Glyzyme Insulin.
(Manufactured by Sanyo Kasei Co., Ltd.) to measure changes in insulin concentration. The results are shown in Table 1.
【0011】[0011]
【表1】 [Table 1]
【0012】表1から解るように、インスリン標準液A
のインスリン濃度は経時変化せず12カ月後でも安定だ
ったが、インスリン標準液Bのインスリン濃度は経時的
に減少した。As can be seen from Table 1, insulin standard solution A
Insulin concentration of No. 2 was stable over 12 months and was stable after 12 months, but the insulin concentration of insulin standard solution B decreased with time.
【0013】[0013]
【発明の効果】本発明の抗原含有溶液の安定保存方法に
よれば、ホルモンや酵素などの失活の激しい抗原も、溶
液状態で1年以上の長期間安定して保存することができ
る。このため、従来行われた凍結乾燥しなくとも安定性
を長期間維持できるようになり、抗原を溶解するという
煩雑な調製操作により生じる濃度の誤差がなくなったた
め、精度と再現性が良い免疫測定ができるようになっ
た。以上の点から、本発明は、特に抗原失活の激しいホ
ルモン、酵素、抗体及びウイルスの標準溶液に適用で
き、濃度変化がないことから精度と再現性の良い臨床検
査測定値を得ることができる。According to the method for stably storing an antigen-containing solution of the present invention, antigens with severe inactivation such as hormones and enzymes can be stably stored in solution for a long period of one year or more. For this reason, the stability can be maintained for a long time without lyophilization, which has been conventionally performed, and the error in concentration caused by the complicated preparation operation of dissolving the antigen has been eliminated, so that immunoassay with good accuracy and reproducibility can be performed. Now you can. In view of the above, the present invention can be applied to standard solutions of hormones, enzymes, antibodies and viruses, which are particularly severe in antigen deactivation, and can obtain clinical test measurement values with high accuracy and reproducibility since there is no concentration change. .
Claims (4)
らなることを特徴とする抗原含有水溶液。1. An antigen-containing aqueous solution comprising an antigen and casein and / or whey protein.
2.00w/v%、ホエイ蛋白濃度が0〜1.00w/
v%である請求項1記載の水溶液。2. The casein concentration in the antigen-containing aqueous solution is 0 to 2.
2.00 w / v%, whey protein concentration 0-1.00 w /
The aqueous solution according to claim 1, which is v%.
載の水溶液。3. The aqueous solution according to claim 1, wherein the antigen is a hormone.
いずれか記載の水溶液。4. The aqueous solution according to claim 1, wherein the antigen is insulin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6164760A JP2645805B2 (en) | 1994-06-22 | 1994-06-22 | Antigen-containing aqueous solution |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6164760A JP2645805B2 (en) | 1994-06-22 | 1994-06-22 | Antigen-containing aqueous solution |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH085634A true JPH085634A (en) | 1996-01-12 |
JP2645805B2 JP2645805B2 (en) | 1997-08-25 |
Family
ID=15799412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6164760A Expired - Fee Related JP2645805B2 (en) | 1994-06-22 | 1994-06-22 | Antigen-containing aqueous solution |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2645805B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2367821A (en) * | 2000-06-30 | 2002-04-17 | Nat Biolog Standards Board | Stabilisation of cytokine solutions by casein |
JP2009180527A (en) * | 2008-01-29 | 2009-08-13 | Sanyo Chem Ind Ltd | Antigen-containing aqueous solution |
WO2023286821A1 (en) | 2021-07-15 | 2023-01-19 | 積水メディカル株式会社 | Composition containing tarc, diluted solution, method for preventing carry over of tarc, adsorption-preventing agent, and continuous analysis method |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6316266A (en) * | 1986-07-09 | 1988-01-23 | Toyobo Co Ltd | Reagent composition for measurement of autoantibody |
-
1994
- 1994-06-22 JP JP6164760A patent/JP2645805B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6316266A (en) * | 1986-07-09 | 1988-01-23 | Toyobo Co Ltd | Reagent composition for measurement of autoantibody |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2367821A (en) * | 2000-06-30 | 2002-04-17 | Nat Biolog Standards Board | Stabilisation of cytokine solutions by casein |
GB2367821B (en) * | 2000-06-30 | 2002-11-20 | Nat Biolog Standards Board | Stabilisation of cytokines by casein |
JP2009180527A (en) * | 2008-01-29 | 2009-08-13 | Sanyo Chem Ind Ltd | Antigen-containing aqueous solution |
JP4568334B2 (en) * | 2008-01-29 | 2010-10-27 | 三洋化成工業株式会社 | Antigen-containing aqueous solution |
WO2023286821A1 (en) | 2021-07-15 | 2023-01-19 | 積水メディカル株式会社 | Composition containing tarc, diluted solution, method for preventing carry over of tarc, adsorption-preventing agent, and continuous analysis method |
Also Published As
Publication number | Publication date |
---|---|
JP2645805B2 (en) | 1997-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rizzetto et al. | Incidence and significance of antibodies to delta antigen in hepatitis B virus infection | |
GB1143938A (en) | Immunochemical reagents and process for their manufacture | |
IE44471B1 (en) | Stable preparation of erythrocytes process for preparing it and its use | |
JP2645805B2 (en) | Antigen-containing aqueous solution | |
JPH0616044B2 (en) | Immunological latex agglutination method | |
JP4890399B2 (en) | Reagent for quality control for detecting HBV antigen and method for producing the same | |
US4757016A (en) | Process for stabilizing the activity of peroxidase in solution | |
JPS5816471B2 (en) | Stabilizer for immunochemical measurement reagents | |
JPS61228356A (en) | Dosage determination reagent by blood agglutination of antibody to bacterial toxin, manufacture thereof and use | |
JPH0467150B2 (en) | ||
JP4568334B2 (en) | Antigen-containing aqueous solution | |
JP4033534B2 (en) | Method for stabilizing human hemoglobin | |
CA1334925C (en) | Process for the determination of thyroxine and a suitable standard solution therefor | |
JPS5933227B2 (en) | Reagents for serological reactions and their manufacturing method | |
JPH0980051A (en) | Solution for stabilizing solid phase immunological reagent | |
JP2902095B2 (en) | Method for preserving test solution containing human hemoglobin and stool lysis buffer used therefor | |
JP2542787B2 (en) | Method for measuring thyroxine (T4) or triiodothyronine (T3) and standard solution therefor | |
EP0176780A1 (en) | A preservative solution for fixed avian erythrocytes for the viral hemagglutination test | |
JP2654181B2 (en) | Detection method of human hemoglobin | |
JPS647759B2 (en) | ||
JP3159750B2 (en) | Method for stabilizing labeled peroxidase and stabilized peroxidase labeled product | |
JP3712963B2 (en) | Aqueous solution containing peroxidase-labeled antibody | |
JP2526179B2 (en) | Peroxidase stabilization method in solution | |
JPH06273418A (en) | Preservation stabilizer | |
JPH09224942A (en) | Stabilization method for human hemoglobin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090509 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100509 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110509 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110509 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120509 Year of fee payment: 15 |
|
LAPS | Cancellation because of no payment of annual fees |